Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Isanas AG has 1 pending office action in Biotechnology & Pharmaceuticals. The record lists 1 distinct examiner and 1 distinct art unit, indicating a single examination path for the current matter.
BAUER, BRIANNA LEE is the busiest examiner and handles the pending action. The focused assignment allows practitioners to tailor claim and evidence strategy to that examiner’s review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17621097 | DRUG COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | BAUER, BRIANNA LEE | 1623 | §103 | Non-Final OA | — | Pending | Dec 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIsanas AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brianna Lee Bauer has the most, with 1 of Isanas AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
